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breast cancer?
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Abstract
Genomic data from breast cancers provide additional prognostic and predictive information that is beginning to
be used for patient management. The question arises whether additional information derived from other ‘omic’
approaches such as metabolomics can provide additional information. In an article published this month in BMC
Cancer, Borgan et al. add metabolomic information to genomic measures in breast tumours and demonstrate, for
the first time, that it may be possible to further define subgroups of patients which could be of value clinically.
See research article: http://www.biomedcentral.com/1471-2407/10/628
Introduction
The major problems in breast cancer are predicting
women at risk more precisely and predicting the pre-
sence of micrometastases at the time of primary surgery,
including whether they will grow in the future and their
responsiveness to systemic therapy. Transcriptomics
have led to improvements of standard prognostic mar-
kers such as tumour size and axillary lymph node status.
In parallel, kits for delineating expression of selected
predictive and prognostic gene expression profiles have
been developed and are commercially available. Clinical
trials (TAYLORX and MINDACT) are in progress to
determine their value for selection of appropriate adju-
vant systemic hormone and chemotherapy. However,
the question arises whether other ‘omics’ such as pro-
teomics and metabolomics can add to the prognostic
and predictive information already available from geno-
mics given the heterogeneity and remaining behavioural
unpredictability of breast tumours, as well as whether
such studies might indicate additional therapeutic tar-
gets or whether adding ‘omic’ platforms together may
be clinically useful? The paper by Borgan et al. [1], pub-
lished this month in BMC Cancer, from two centres in
Norway is the first attempt to assess the interactive
value of transcriptomics and metabolomics in a series of
primary breast cancers.
Metabolomics
Metabolomics is the study of the metabolic changes which
occur in living systems as a result of gene and protein
expression and may enhance the information provided by
genomics and proteomics. The metabolome may be the
most sensitive measure of cellular phenotype, and meth-
ods are evolving to measure the metabolome of a single
cell. Analytical methods for metabolomics analysis include
liquid chromatography-mass spectroscopy (hundreds of
metabolites with multiple unknown peaks), gas chromato-
graphy-mass spectroscopy (GC-MS approximately 120 to
2 0 0m e t a b o l i t e s )a n dt h em e t h o du s e di nt h ep a p e rb y
Borgan et al. which uses high resolution magic angle spin-
ning, magnetic resonance spectroscopy (HR-MAS MRS.
approximately 20 to 40 metabolites) [2]. The advantage of
the latter technique is that it can be carried out on stan-
dard preparations of tissues without tissue extraction and
the derivatisation necessary for GC-MS. In addition, the
results can be available in less than one hour, although the
assays have less resolution and sensitivity compared with
the more time-consuming GC-MS.
Metabolomics in cancer
Previous studies have demonstrated that metabolomic
analysis can distinguish between cancer and non-cancer
tissues but do not readily distinguish grade and stage
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any medium, provided the original work is properly cited.[3-7]. In the current study, Borgan et al. focussed mainly
on oestrogen receptor positive (ER + ve) tumours
defined as Luminal A type by genomic analysis. ER + ve
breast cancers are the largest group of invasive disease
and there is a need to distinguish those that will and
will not respond to hormone therapy for a plethora of
reasons. Metabolomic analysis indicated that the Lumi-
nal A subtype could be separated into three groups
using multivariate analysis and hierarchical clustering.
The metabolites which helped distinguish between the
three groups included a and b glucose aminoacids,
myo-inositol and lipid residues. Gene ontology (GO)
enrichment analyses using Gene Set Analysis (GSA)
indicated that one subtype of luminal A was enriched
for biological processes related to cell cycle and DNA
repair and thus may be a group resistant to hormone
therapy. The investigators also assessed the levels of
eight metabolites (high to low) in relation to the tran-
scriptional activity of each ER + ve tumour. Myo-inosi-
tol and taurine high, ranked with GO terms related to
extracellular matrix and choline high was associated
with GO terms related to the cell cycle such as ‘cell
cycle process’ and ‘chromosome segregation’. The results
summarised above and discussed in more detail by Bor-
gan and colleagues this month in BMC Cancer [1] are
novel because of the reported analytical interactions
between genomic and metabolomic results. Their clini-
cal significance will be shown when analyses are per-
formed on frozen tumours saved from patients with
long-term follow up.
One general analytical problem with this approach is
the variable amount of epithelium and stroma in the
samples, since recent evidence suggests marked differ-
ences and interactions between the metabolism of
tumour cells and tumour associated fibroblasts [7]. In
addition, it may also be difficult to make definitive state-
ments concerning the value of the metabolome without
also assessing additional metabolites using more sensi-
tive techniques such as GC-MS [4]. Also, since we know
from genomic studies that the stroma gives prognostic
and predictive information over and above that given by
the epithelium, there is a need to explore measuring
metabolites after separation of these two compartments
in tumours. Since only relatively small tumour samples
are required it should be possible to assess the effects of
various treatments on the metabolome in the interval
between biopsy and definitive surgery two to three
weeks later: so-called, ‘window studies’.
Conclusions
Using metabolomics to improve prognostic prediction in
cancer looks to be a promising approach, however,
further studies are required to determine the precise
value of metabolomics in the management of patients
with breast cancer.
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